A recent study confirms lenacapavir's effectiveness against HIV and highlights the capsid as a promising drug target despite resistance.

Researchers revealed that HIV integrase forms structural filaments within the viral capsid, enabling viral infectivity. The discovery uncovers a new drug target, opening possibilities for ...

VectorY Therapeutics has signed an agreement securing an exclusive option to assess Shape Therapeutics’ SHP-DB1 adeno-associated virus (AAV) capsid for vectorised antibody payloads targeting three ...

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it.

Researchers develop a large dodecahedral structure through the self- assembly of metal ions and peptides, with potential implications in drug delivery systems and molecular transportation. Controlling ...